ASCO 2022 | Results of N-803, an IL-15RαFc superagonist, with BCG in BCG-unresponsive CIS and NMIBC

Karim Chamie, MD, University of California Los Angeles, Los Angeles, CA, discusses efficacy and safety of intravesical bacillus calmette-guerin (BCG) and N-803 in patients with BCG-unresponsive high-grade nonmuscle-invasive bladder cancer (NMIBC) and papillary disease. 160 patients with BCG-unresponsive NMIBC were treated with BCG+N-803 via a urinary catheter. It was found that 99% of these patients had bladder cancer-specific overall survival at two years, and cystectomy was avoided in over 90% of patients. Moreover, CIS patients with BCG-unresponsive NMIBC, who typically have limited treatment options, had a 71% complete response rate to BCG+N-803. Furthermore, patients with papillary disease had a 53% disease-free rate at 18 months. The safety profile of BCG+N-803 exceeds that of other available intravesical and systemic options for BCG-unresponsive NMIBC. interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL